Navigation Links
Amsterdam Molecular Therapeutics Announces Negative Equity Position
Date:12/14/2011

AMSTERDAM, December 15, 2011 /PRNewswire/ --

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the Company has a negative equity position, as a result of ongoing loss-making operations. The development of this negative equity position is in line with previous guidance that the Company has cash into early 2012, and is exploring alternatives for additional financing.

AMT announced on November 17, 2011 that its cash position at September 30, 2011 amounted to € 3.8 million, and AMT continues to be loss making and to experience net cash outflows. At December 12, 2011 AMT's cash position amounted to € 2.1 million; AMT does not have any loan, credit or other borrowing facilities other than the € 5 million convertible loan issued in December 2009.

The Company continues partnering discussions with pharma companies. At this time, AMT anticipates that it may be possible to conclude a partnership for its hemophilia B program during the first half of 2012, provided that additional funding can be secured in the meantime. AMT is also looking at additional collaborations with academic groups, which would contribute towards the short-term funding of its GDNF program for up to three indications.

AMT is continuing to explore all options with regard to the business, its financing, and support from existing shareholders. This includes selling all or part of the business, and raising additional capital in conjunction with its bankers and investors. AMT is also tracking opportunities for funding, from non-dilutive sources such as grants, and collaborations with partners. The Company has already taken appropriate action to reduce its costs, and the number of employees has decreased by approximately 50 per cent to 45 staff. Further cost reductions are possible but the savings would not provide a significantly longer runway for seeking a funding solution. Additional reductions m
'/>"/>

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
2. Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline
3. Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
4. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
5. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
6. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
7. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
8. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
9. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
10. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
11. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... The ... the use of special anti-vascular endothelial growth factor agents given by injection into ... does not have a scientific protocol for the many millions diagnosed with it. ...
(Date:9/2/2015)... , Sep. 02, 2015 ... ) has announced the addition of Jain ... Markets and Companies" to their offering. ... several technologies besides fluorescence in situ hybridization ... FISH. Molecular cytogenetics includes application of nanobiotechnology, ...
(Date:9/2/2015)... Sept. 2, 2015  Neurotech Pharmaceuticals, Inc., announced ... the multicenter Phase 2 clinical trial of NT-503 ... of recurrent subfoveal choroidal neovascularization secondary to age ... unique vascular endothelial growth factor (VEGF) receptor protein ... "This landmark proof-of-concept study will evaluate NT-503 ...
(Date:9/2/2015)... FRANCISCO, Calif. , Sept. 2, 2015 ... Bonnie H. Anderson , president and chief executive ... Conference on Wednesday, September 16, 2015 at 10:30 a.m. ... The live audio webcast and subsequent ... . The webcast will be available shortly after conclusion ...
Breaking Biology Technology:StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Veracyte to Present at Morgan Stanley Global Healthcare Conference 2
... Advanced Life Sciences Holdings, Inc. (OTCBB: ... and commercialization of novel drugs in the therapeutic areas ... it has suspended operations and terminated its staff due ... (Logo:   http://photos.prnewswire.com/prnh/20080218/ALSLOGO ) "We presently ...
... SAINT PAUL, Minn., May 5, 2011 Image Sensing Systems, ... for its first quarter ended March 31, 2011. ... first quarter was $6.1 million compared to $5.4 million for ... $2.7 million in the first quarter of 2011 compared to ...
... May 5, 2011 In parts of the ... often misdiagnosed. Such misdiagnosis is a waste not only of ... of another mosquito-borne viral infection called chikungunya—its high fever, joint ... mimic the clinical profile of dengue. Recovery from the acute ...
Cached Biology Technology:Advanced Life Sciences Suspends Operations 2Image Sensing Systems Announces First Quarter Financial Results 2Image Sensing Systems Announces First Quarter Financial Results 3Image Sensing Systems Announces First Quarter Financial Results 4Image Sensing Systems Announces First Quarter Financial Results 5SRI International and CTK Biotech Developing Low-Cost Diagnostic for Hard-to-Diagnose Chikungunya Virus 2SRI International and CTK Biotech Developing Low-Cost Diagnostic for Hard-to-Diagnose Chikungunya Virus 3
(Date:8/18/2015)... , Aug. 18, 2015  Navitas today ... contributor to the Submission Content Management webinar ... a non-profit forum. Dedicated to the Implementation of ... neutral platform for industry, vendors, health authorities, ... and work towards a standard method of ...
(Date:8/12/2015)... , August 12, 2015 As ... mobile payment innovation and advanced biometrics technology is accelerating ... way consumers rely on using their credit cards, the ... the future for payment services led by companies in ... ), :  Google, Inc. (NASDAQ: GOOG ), Apple ...
(Date:8/10/2015)... , August 10, 2015 ... Eye Tracking Technology for more than two decades, announces ... for integration into all consumer display formats. The SMI ... integration of eye tracking into consumer tablets, laptops, desktop ... smart glasses. Omnivision,s leading sensor technology contributes to the ...
Breaking Biology News(10 mins):Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
... The stem cells that produce bird feathers have been visualized ... in a scientific journey that may ultimately shed light on ... 15 issue of the journal Nature, was performed by a ... Medicine of the University of Southern California. , "What we ...
... drought, otherwise harmless snails likely killed off thousands of ... years. , Periwinkle snails, known to science as Littoraria ... drought, which lasted from 1999 to 2001, weakened and ... so extensively that the snails moved from finishing off ...
... Johns Hopkins' senior hospital epidemiologist and flu expert is ... as the best means of protecting patients and hospital ... Studies by other United States researchers show that voluntary ... year, nearly 40,000 Americans die from influenza, many of ...
Cached Biology News:USC researchers track down the stem cells that create feathers 2USC researchers track down the stem cells that create feathers 3Research: Snails were overlooked contributors to marsh destruction 2Research: Snails were overlooked contributors to marsh destruction 3Johns Hopkins flu expert calls for mandatory vaccination of health care workers 2Johns Hopkins flu expert calls for mandatory vaccination of health care workers 3
All-in-one mix, removes primers and dNTPs from PCR product for following direct sequencing...
...
...
... APAgene kits are designed to rapidly ... using our patented APA Technology. APAgene provides ... competitive price. All necessary ingredients are provided ... kit can be used for insert-end amplification ...
Biology Products: